Clinical trial · Observational
Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations
NCT04113486CI-TRIAL-00119667ENRCrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to observe the difference between NMAP (nicotinamide metabolism associated protein) serum levels in primary diagnosed renal cancer patients and non-renal cancer patient controls, plot the ROC curve and establish appropriate cut-off values.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Renal Cell | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood test | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Renal cancer group
- description
- Patients which imaging studies have found renal mass, plan to receive surgery (except for radiofrequency ablation, cryoablation, etc.), about 100.
- interventionNames
- Other: Blood test
- label
- Urothiasis group
- description
- Patients which imaging studies have found renal or ureteral stones, and rule out of renal mass, about 100.
- interventionNames
- Other: Blood test
- label
- Renal cysts group
- description
- Patients which imaging studies have found renal cysts (simple or complex) about 100.
- interventionNames
- Other: Blood test
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. The tumor group patients were found to have renal or hepatic mass, plan to receive surgical treatment (except for radiofrequency ablation, cryoablation, etc., which were not available for pathological examination). The control group patients were ruled out of tumor based on radiological tests and commonly used tumor biomarkers 2. Age ≥ 18 years old and able to provide written informed consent; 3. Have not received any systemic or topical treatment for kidney/liver tumors. 4. Cardiopulmonary, liver and kidney functions are able to tolerate surgery and can comply with research requirements. Exclusion Criteria: 1. The investigators believe that the subject may be unsuitable for inclusion due to severe concurrent diseases, infections, and etc. 2. The subjects is known or suspected of other malignancies. 3. There has been another history of malignancy in the past 5 years. 4. Major surgery (surgery requiring general anesthesia) was performed within 4 weeks prior to screening visits.
References
Publications (0)
Data not yet available
No reference posted for this study.